Windtree initiates phase II trial of lucinactant for COVID-19-associated acute lung injury Jan. 7, 2021
Phase IIb/III trial of Zyesami for respiratory failure in critical COVID-19 completes enrollment Dec. 30, 2020
National Institute of Pharmaceutical R&D describes M3 antagonists/beta2-adrenoceptor agonists Dec. 28, 2020
RSS